GBS INC (GBS) Stock Price & Overview
NASDAQ:GBS • US36151G1058
Current stock price
The current stock price of GBS is 0.4732 USD. Today GBS is down by -0.04%. In the past month the price increased by 13.97%. In the past year, price decreased by -76.8%.
GBS Key Statistics
- Market Cap
- 7.046M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.56
- Dividend Yield
- N/A
GBS Stock Performance
GBS Stock Chart
GBS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GBS. When comparing the yearly performance of all stocks, GBS is a bad performer in the overall market: 88.45% of all stocks are doing better.
GBS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GBS. Both the profitability and financial health of GBS have multiple concerns.
GBS Earnings
GBS Forecast & Estimates
0 analysts have analysed GBS and the average price target is 4.59 USD. This implies a price increase of 869.99% is expected in the next year compared to the current price of 0.4732.
For the next year, analysts expect an EPS growth of 44.09% and a revenue growth -100% for GBS
GBS Groups
Sector & Classification
GBS Financial Highlights
Over the last trailing twelve months GBS reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 17.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1900.05% | ||
| ROA | -67.24% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GBS Ownership
GBS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.66 | 174.966B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.91 | 163.009B | ||
| SYK | STRYKER CORP | 22.96 | 132.986B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.12 | 93.897B | ||
| IDXX | IDEXX LABORATORIES INC | 38.76 | 45.587B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.93 | 45.039B | ||
| BDX | BECTON DICKINSON AND CO | 11.39 | 44.257B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.29 | 33.688B | ||
| RMD | RESMED INC | 18.75 | 33.544B | ||
| DXCM | DEXCOM INC | 24.82 | 24.292B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.24 | 18.455B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 30.51 | 13.926B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GBS
Company Profile
GBS, Inc. operates as a biosensor diagnostic technology company. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2020-12-23. The Company’s products include Biosensor Platform Technology, Saliva Glucose Test (SGT) and Saliva Glucose Biosensor (SGB). The Biosensor Platform is a SGB-based modified Organic Thin Film Transistor (OTFT). The OTFT structure consists of a source and drain electrode, a semiconducting layer, a gate electrode, an optional separation (or dielectric) layer, all printed on a substrate material and superimposed by a polyelectrolyte membrane/enzyme layer onto which the analyte is placed. The SGT consists of SGB, which is a single use disposable saliva biosensor, and Software app, which is a smart device or a dedicated reader that interfaces the SGB with its digital information system. The SGB interacts with the glucose in the saliva and initiates an electrochemical reaction, producing an electrical signal directly correlated to the amount of glucose present in the saliva.
Company Info
IPO: 2020-12-23
GBS INC
142 West 57th Street, 11th Floor
New York City NEW YORK US
Employees: 12
Phone: 16462336971.0
GBS INC / GBS FAQ
What does GBS do?
GBS, Inc. operates as a biosensor diagnostic technology company. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2020-12-23. The Company’s products include Biosensor Platform Technology, Saliva Glucose Test (SGT) and Saliva Glucose Biosensor (SGB). The Biosensor Platform is a SGB-based modified Organic Thin Film Transistor (OTFT). The OTFT structure consists of a source and drain electrode, a semiconducting layer, a gate electrode, an optional separation (or dielectric) layer, all printed on a substrate material and superimposed by a polyelectrolyte membrane/enzyme layer onto which the analyte is placed. The SGT consists of SGB, which is a single use disposable saliva biosensor, and Software app, which is a smart device or a dedicated reader that interfaces the SGB with its digital information system. The SGB interacts with the glucose in the saliva and initiates an electrochemical reaction, producing an electrical signal directly correlated to the amount of glucose present in the saliva.
Can you provide the latest stock price for GBS INC?
The current stock price of GBS is 0.4732 USD. The price decreased by -0.04% in the last trading session.
Does GBS INC pay dividends?
GBS does not pay a dividend.
How is the ChartMill rating for GBS INC?
GBS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for GBS stock?
The Revenue of GBS INC (GBS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for GBS INC?
GBS INC (GBS) has a market capitalization of 7.05M USD. This makes GBS a Nano Cap stock.
Who owns GBS INC?
You can find the ownership structure of GBS INC (GBS) on the Ownership tab.